LLY

807.7

-1.21%↓

UNH

558.33

-1.43%↓

JNJ

158.98

-0.63%↓

NVO

110.19

-1.57%↓

ABBV

202.14

-0.54%↓

LLY

807.7

-1.21%↓

UNH

558.33

-1.43%↓

JNJ

158.98

-0.63%↓

NVO

110.19

-1.57%↓

ABBV

202.14

-0.54%↓

LLY

807.7

-1.21%↓

UNH

558.33

-1.43%↓

JNJ

158.98

-0.63%↓

NVO

110.19

-1.57%↓

ABBV

202.14

-0.54%↓

LLY

807.7

-1.21%↓

UNH

558.33

-1.43%↓

JNJ

158.98

-0.63%↓

NVO

110.19

-1.57%↓

ABBV

202.14

-0.54%↓

LLY

807.7

-1.21%↓

UNH

558.33

-1.43%↓

JNJ

158.98

-0.63%↓

NVO

110.19

-1.57%↓

ABBV

202.14

-0.54%↓

Search

Merck & Co Inc.

Open

Sector Healthcare

101.87 -0.4

Overview

Share price change

24h

Current

Min

101.87

Max

102.49

Key metrics

By Trading Economics

Income

-2.3B

3.2B

Sales

550M

17B

P/E

Sector Avg

137.56

104.138

EPS

1.57

Dividend yield

2.712

Profit margin

18.95

Employees

72,000

EBITDA

491M

7.4B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+30.9 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.71%

1.72%

Next Dividend date

6 Jan 2025

Next Ex Dividend date

12 Dec 2024

Market Stats

By TradingEconomics

Market Cap

836M

258B

Previous open

102.27

Previous close

101.87

News Sentiment

By Acuity

37%

63%

124 / 390 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Merck & Co Inc. Chart

Past performance is not a reliable indicator of future results.

Related News

23 Oct 2024, 14:04 UTC

Acquisitions, Mergers, Takeovers

Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences

31 Oct 2024, 12:07 UTC

Top News
Earnings

Update: Merck Tops Earnings Estimates but Lowers Full-Year Guidance -- Barrons.com

31 Oct 2024, 10:49 UTC

Top News
Earnings

Merck Tops Earnings Estimates but Lowers Full-Year Guidance -- Barrons.com

31 Oct 2024, 10:31 UTC

Earnings

Merck Posts 79c/Share 3Q Charge Related to Business Development Transactions >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Januvia/Janumet Sales Down 42% >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Animal Health Sales $1.49B >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Keytruda Sales $7.43B >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Pharmaceutical Sales $14.94B >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Pharmaceutical Sales Up 5% >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Net $3.16B >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Gardasil/Gardasil 9 Sales $2.31B >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Adj EPS $1.57 >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q EPS $1.24 >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Gardasil/Gardasil 9 Sales Down 11% >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Januvia/Janumet Sales $482M >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck Sees FY Rev $63.6B-$64.1B >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Keytruda Sales Up 17% >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck Sees FY Adj EPS $7.72-Adj EPS $7.77 >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Animal Health Sales Up 6% >MRK

31 Oct 2024, 10:30 UTC

Earnings

Merck 3Q Sales $16.7B >MRK

24 Oct 2024, 13:50 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

3 Oct 2024, 19:02 UTC

Acquisitions, Mergers, Takeovers

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

3 Oct 2024, 18:20 UTC

Acquisitions, Mergers, Takeovers

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

1 Oct 2024, 10:46 UTC

Acquisitions, Mergers, Takeovers

Merck to Post 3Q Charge of About 28c/Share on Curon Deal >MRK

1 Oct 2024, 10:46 UTC

Acquisitions, Mergers, Takeovers

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, From Curon Biopharmaceutical

30 Sept 2024, 21:02 UTC

Top News

FOMO on China Stock Rally? Think Twice About Buying In. -- Barrons.com

12 Sept 2024, 15:02 UTC

Top News

Moderna Cost Cuts Fail to Restore Investor Trust -- Heard on the Street -- WSJ

12 Sept 2024, 10:00 UTC

Top News

Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com

9 Sept 2024, 17:55 UTC

Top News

A Better Drug Than Merck's Blockbuster Keytruda? Not So Fast -- WSJ

9 Sept 2024, 09:17 UTC

Top News

Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial -- Barrons.com

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

30.9% upside

12 Months Forecast

Average 133.36 USD  30.9%

High 155 USD

Low 110 USD

Based on 17 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

14

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

98.6 / 103.86Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

124 / 390 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.